Table 1 List and characteristics of AMPs used in this study. Their abbreviation, described mode of action, and clinical relevance (for details see Supplementary Data 7).
Name of AMP | Abbreviation | Mode of action | Clinical relevance |
|---|---|---|---|
Apidaecin IB | AP | Inhibits protein biosynthesis by targeting ribosomes; Interacts with DnaK, GroEL/GroES, FtsH | Yes |
Bactenecin 5 | BAC5 | Inhibits protein and RNA synthesis | n.a. |
CAP18 | CAP18 | Disrupts cell membrane | Yes |
Cecropin P1 | CP1 | Disrupts cell membrane | n.a. |
Human beta-defensin-3 | HBD-3 | Disrupts cell membrane; Inhibits lipid II in peptidoglycan biosynthesis | n.a. |
Indolicidin | IND | Inhibits DNA and protein synthesis; Disrupts cell membrane; Inhibits septum formation | Yes |
LL-37 human cathelicidin | LL37 | Disrupts cell membrane; Induces ROS formation | Yes |
Peptide glycine-leucine amide | PGLA | Disrupts cell membrane | n.a. |
Pexiganan | PEX | Disrupts cell membrane | Yes |
Pleurocidin | PLEU | Disrupts cell membrane; Induces ROS formation; Inhibits protein and DNA synthesis | n.a. |
Polymyxin B | PXB | Disrupts cell membrane; Induces ROS formation | Yes |
PR-39 | PR39 | Inhibits protein and DNA synthesis | n.a. |
Protamine | PROA | Affects cellular respiration and glycolysis; Disrupts cell envelop | n.a. |
R8 | R8 | n.a. | n.a. |
Tachyplesin II | TPII | Disrupts cell membrane | n.a. |
